Emergent BioSolutions Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 28/100
What the filing says
Emergent BioSolutions received a modification exercising an option under its existing IDIQ contract (W911SR24D0001) with the U.S. Department of War to supply BioThrax (anthrax vaccine) valued at up to $22.3 million. First delivery of ~$7.4 million occurs in 2026; remaining deliveries expected in 2027. This complements an August 2026 BARDA contract modification worth ~$24 million for CYFENDUS (adjuvanted anthrax vaccine).
Why this rating
Award is ~6.5% of company's $342.7M market cap. Meaningful revenue but routine government contract exercise under existing IDIQ framework; limited visibility beyond 2027.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.